Mercado de tratamiento del herpes labial (para el virus HSV 1) en América del Norte: tendencias de la industria y pronóstico hasta 2030

Análisis y perspectivas del mercado de tratamiento del herpes labial (para el virus HSV 1) en América del Norte

La creciente prevalencia e incidencia de infecciones por herpes labial ha aumentado la demanda del mercado. El aumento del gasto sanitario para mejorar los servicios sanitarios también contribuye al crecimiento del mercado. Los principales actores del mercado se centran en diversos lanzamientos y aprobaciones de servicios durante este período crucial. Además, el aumento de las inversiones en I+D farmacéutica y en investigación en ciencias de la vida también contribuye a la creciente demanda de tratamientos para el herpes labial.

Se espera que el mercado de tratamiento del herpes labial (para el virus HSV 1) en América del Norte crezca en el año de pronóstico debido al aumento de los actores del mercado y la disponibilidad de servicios avanzados. Junto con esto, los fabricantes están involucrados en actividades de I+D para lanzar productos novedosos al mercado. La proliferación de modos de transmisión del HSV está impulsando aún más el crecimiento del mercado. Sin embargo, la falta de conocimiento sobre la aparición y los síntomas del herpes labial y su tratamiento podría obstaculizar el crecimiento del mercado en el período de pronóstico.

Se espera que el mercado de tratamiento del herpes labial (para el virus HSV 1) de América del Norte gane crecimiento de mercado en el período de pronóstico de 2023 a 2030. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 5,6% en el período de pronóstico de 2023 a 2030 y se espera que alcance los USD 690,51 millones para 2030 desde USD 446,54 millones en 2022.

Market Definition

Cold sores or oral herpes are small blisters-like abrasions that occur due to the infection caused by the Herpes Simplex Virus (HSV). Cold sores generally occur on the face, around the lips, chin, cheeks, and nostrils. They generally cause pain and itching before they burst. HSV is one of the most common viruses found to affect the global population and it is endemic throughout the world. Up to 90% of people around the world have at least one form of HSV. It generally infects the pediatric population worldwide, but according to WHO, people aged 30-49 are at higher risk now for catching the virus, and the prevalence of HSV increases with age.

North America Cold Sore Treatment (for HSV 1 Virus) Market Dynamics

DRIVERS

• Growing Prevalence of Cold Sore Infection

A group of small, hurting blisters caused by the Herpes Simplex Virus (HSV) is called cold sores. They are also called fever blisters or oral herpes. HSV is one of the most common viruses found to affect the global population and is endemic worldwide.

For instance,

• According to WHO, people under 50 infected with HSV-1 are estimated to be more than 3.7 billion globally (67%)

• According to the Centers for Disease Control and Prevention (CDC), data from the National Health and Nutrition Examination Survey showed that the prevalence of HSV-1 is found to be more in women as compared to men globally. The prevalence of HSV also increases with age.

• According to CDC, HSV-1 prevalence in the U.S. among people aged 0-49 in 2012 includes 178 million women, which means 49% of women population

With these instances, we can conclude that the growing prevalence of cold sore infections is driving the market growth.

• Proliferation in Modes of Transmission of Herpes Simplex Virus

An infectious virus can be transmitted in different modes, from its natural reservoir to a susceptible host. The spread of HSV infection relies on the intimate, personal interaction of a susceptible person with someone who excretes HSV transmission modes have different classifications, which include direct and indirect transmission.

HSV is commonly transmitted through direct transmission, including direct contact or droplet spread. The primary mode of HSV-1 transmission is via oral-to-oral contact inducing infection with oral herpes, by contact with the HSV in saliva, sores, and surfaces in or around the mouth. Also, unhygienic practices, unprotected sexual intercourse, and oral sex are the major modes coming up which are increasing the transmission of HSV among people. Moreover, HSV can be transmitted via contact, such as kissing, eating from the same utensils, sharing cups, towels, or from toilet seats, and sharing lip balm. Thus, the increase in infectious disease transmission modes is anticipated to drive market growth.

OPPORTUNITY

• Increasing Use of Cold Sore Patches

The increasing cases of cold sores have created numerous opportunities for the market players and potentially surged the demand for treatment options required to treat the HSV-1 infection or associated disease. Due to this reason, various key market players are investing more in HSV research to come up with novel treatment options.

Several technological advancements are taking place for the treatment of cold sores, including all medical research aimed at introducing new technologies (vaccines, therapy, drugs, and patches) for the treatment of cold sores. Patches are consistently in demand for their effectiveness against cold sores.

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for market growth in the forecast period of 2023-2030.

RESTRAINT/CHALLENGE

• The Dearth of Awareness about the Onset and Symptoms of Cold Sore and its Treatment

The dearth of awareness about the onset and symptoms of cold sore and the patent termination of some of the marketed drugs will impede the market growth rate. Additionally, side effects associated with medications used for treating cold sores will further challenge the market growth.

Recent Developments

• In October 2022, GSK plc. and Tempus, a U.S.-based precision medicine company, entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment, and identify drug targets. This will contribute to GSK’s R&D success rate and provide patients with more personalized treatment faster.
• In July 2022, Haleon Group of Companies announced the completion of the spin-off of the healthcare business from GSK Group to Haleon Group. Haleon is the world's leading consumer health company, with brands trusted by millions of consumers worldwide. Its product range includes five main categories- oral health, pain relief, respiratory health, digestive health, and others, as well as vitamins, minerals, and dietary supplements (VMS). Its long-standing brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax, and Centrum are based on sound science, innovation, and a deep understanding of people.

North America Cold Sore Treatment (for HSV 1 Virus) Market Scope

The North America cold sore treatment (for HSV 1 virus) market is segmented into product type, route of administration, type, gender, drug type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Medications
• Ointments
• Creams
• Medicated Lip Balms
• Cold Sore Patches
• Non-Medicated Products

Based on product type, the market is segmented into medications, ointments, creams, medicated lip balms, cold sore patches, and non-medicated products.

Route of Administration

• Oral
• Topical
• Others

Based on route of administration, the market is segmented into oral, topical, and others.

Type

• Prescription Drugs
• Over The Counter (OTC) Drugs

Based on type, the market is segmented into prescription drugs and Over The Counter (OTC) drugs.

Gender

• Male
• Female

Based on gender, the market is segmented into male and female.

Drug Type

• Branded
• Generics

Based on drug type, the market is segmented into branded and generics.

End User

• Hospitals
• Specialty Clinics
• Homecare Setting
• Others

Based on end user, the market is segmented into hospitals, specialty clinics, homecare setting, and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

North America Cold Sore Treatment (for HSV 1 Virus) Market Regional Analysis/Insights     

The North America cold sore treatment (for HSV 1 virus) market is analyzed and market size insights and trends are provided by country, product type, route of administration, type, gender, drug type, end user, and distribution channel as referenced above.

The U.S. is dominating the market in North America in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of cold sore infections in the region and rapid R&D, which is boosting market growth.

La sección de países del informe también proporciona factores individuales que impactan en el mercado y cambios en las regulaciones del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos, como las ventas nuevas y de reemplazo, la demografía del país, la epidemiología de las enfermedades y los aranceles de importación y exportación, son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para cada país. Además, la presencia y disponibilidad de marcas de América del Norte y los desafíos que enfrentan debido a la alta competencia de las marcas locales y nacionales, y el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de tratamiento del herpes labial (para el virus HSV 1) en América del Norte

El panorama competitivo del mercado de tratamiento del herpes labial (para el virus HSV 1) en América del Norte proporciona detalles de los competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, la presencia en América del Norte, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado.

Algunos de los principales actores que operan en el mercado de tratamiento del herpes labial (para el virus HSV 1) en América del Norte son GSK plc., Novartis AG, Viatris Inc., Hikma Pharmaceuticals PLC, HRA Pharma, Quantum Health, URGO, Apotex Inc., Church & Dwight Co., Inc., Bausch Health Companies Inc., Zydus Pharmaceuticals Inc., Haleon Group of Companies, Amparo medical Technologies, Teva Pharmaceuticals USA, Inc., Carma Labs Inc. y Blistex Inc., entre otros.

SKU-60513